Opiate substitution treatment (OST) programs could provide opportunities for management of comorbidities, such as hepatitis C virus (HCV) infection, in people who inject drugs. We aimed to prospectively evaluate the real-life feasibility of interferon/ribavirin-based HCV treatment in OST recipients, with a special focus on psychiatric status and health-related quality of life.
Patients from a cohort of OST recipients from three cities in Sweden were selected for HCV treatment on the basis of structured investigation for HCV-related liver disease. Therapy was delivered in collaboration between infectious disease and OST clinics, with monitoring for completion and adherence, treatment response, adverse events, health-related quality of life (HRQoL) (SF-36) and signs of depression (MADRS-S), or relapse into drug abuse. The primary endpoint was completion of prescribed treatment; the secondary endpoints were sustained virological response (SVR), adherence, and incidence of depression.
Among 69 patients with an indication for antiviral therapy, 41 initiated treatment; 34/41 (83%) completed treatment and 19/41 (46%) achieved SVR. Adequate adherence was observed in 29/41 patients (71%). Two serious adverse events occurred, including one death because of liver failure. Baseline scores for self-assessed health were low, with a significant reduction during treatment. Seventy-one percent of patients (29/41) fulfilled the criteria for clinically significant depression at some time point during treatment. Baseline scores for HRQoL/MADRS-S were associated with treatment completion, SVR, and depression during treatment.
Despite the low HRQoL and the high occurrence of depression, HCV treatment was feasible and showed satisfactory rates of completion in this cohort of unselected OST recipients.
aDepartment of Clinical Sciences, Section for Infectious Diseases, Lund University
cDepartment of Clinical Microbiology, Skane University Hospital, Malmö
dDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
eAddiction Center, Sahlgrenska University Hospital, Gothenburg
fDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm
gStockholm Center for Dependency Disorders, Stockholm, Sweden
Correspondence to Anna Jerkeman, MD, Department of Clinical Sciences, Section for Infectious Diseases, Lund University, SE-205 02 Malmö, Sweden Tel: +46 403 37736; fax: +46 403 37363; e-mail: email@example.com
Received January 11, 2014
Accepted February 5, 2014